Tolerance, adherence, and acceptability of a ketogenic 2.5:1 ratio, nutritionally complete, medium chain triglyceride‐containing liquid feed in children and adults with drug‐resistant epilepsy following a ketogenic diet

Author:

Griffen Corbin1ORCID,Schoeler Natasha E.23ORCID,Browne Robert1,Cameron Tracy45,Kirkpatrick Martin4,Thowfeek Seema6,Munn Judith6,Champion Helena7,Mills Nicole7,Phillips Siân8,Air Linda9,Devlin Anita9,Nicol Claire9,Macfarlane Susan4,Bittle Victoria10,Thomas Phillipa10,Cooke Lisa10,Ackril Julia11,Allford Astrid11,Appleyard Vanessa11,Szwec Clare1,Atwal Kiranjit12,Hubbard Gary P.1ORCID,Stratton Rebecca J.113ORCID

Affiliation:

1. Clinical Research, Nutricia Ltd. Trowbridge UK

2. UCL Great Ormond Street Institute of Child Health London UK

3. Great Ormond Street Hospital for Children London UK

4. Tayside Children's Hospital Dundee UK

5. Royal Aberdeen Children's Hospital Aberdeen UK

6. The Barberry, Birmingham and Solihull Mental Health NHS Foundation Trust Birmingham UK

7. Cambridge University Hospitals NHS Foundation Trust Cambridge UK

8. Southampton Children's Hospital, Southampton General Hospital Southampton UK

9. Great North Children's Hospital Newcastle Upon Tyne UK

10. Bristol Royal Hospital for Children Bristol UK

11. Birmingham Women's and Children's NHS Trust Birmingham UK

12. Independent Researcher Phoenix Arizona USA

13. University of Southampton Southampton UK

Abstract

AbstractObjectiveTo investigate incorporating a ready‐to‐use 2.5:1 ratio liquid feed into a ketogenic diet (KD) in children and adults with drug‐resistant epilepsy.MethodsFollowing a three‐day baseline, patients (n = 19; age: 19 years [SD 13], range: 8–46 years) followed a KD for 28 days (control period), then incorporated ≥200 mL/day of a ready‐to‐use liquid feed, made with a ratio of 2.5 g of fat to 1 g of protein plus carbohydrate and including medium chain triglycerides ([MCTs]; 25.6% of total fat/100 mL) for 28 days as part of their KD (intervention period). Outcome measures (control vs intervention period) included gastrointestinal (GI) tolerance, adherence to KD and intervention feed, dietary intake, blood ß‐hydroxybutyrate (BHB) concentration, seizure outcomes, health‐related quality of life (HRQoL), acceptability and safety.ResultsCompared to the control period, during the intervention period, the percentage of patients reporting no GI symptoms increased (+5% [SD 5], p = 0.02); adherence to the KD prescription was similar (p = 0.92) but higher in patients (n = 5) with poor adherence (<50%) to KD during the control period (+33% [SD 26], p = 0.049); total MCT intake increased (+12.1 g/day [SD 14.0], p = 0.002), driven by increases in octanoic (C8; +8.3 g/day [SD 6.4], p < 0.001) and decanoic acid (C10; +5.4 g/day [SD 5.4], p < 0.001); KD ratio decreased (p = 0.047), driven by a nonsignificant increase in protein intake (+11 g/day [SD 44], p = 0.29); seizure outcomes were similar (p ≥ 0.63) but improved in patients (n = 6) with the worst seizure outcomes during the control period (p = 0.04); and HRQoL outcomes were similar. The intervention feed was well adhered to (96% [SD 8]) and accepted (≥88% of patients confirmed).SignificanceThese findings provide an evidence‐base to support the effective management of children and adults with drug‐resistant epilepsy following a KD with the use of a ready‐to‐use, nutritionally complete, 2.5:1 ratio feed including MCTs.Plain language summaryThis study examined the use of a ready‐to‐use, nutritionally complete, 2.5:1 ratio (2.5 g of fat to 1 g of protein plus carbohydrate) liquid feed, including medium chain triglycerides (MCTs), into a ketogenic diet (KD) in children and adults with drug‐resistant epilepsy. The results show that the 2.5:1 ratio feed was well tolerated, adhered to, and accepted in these patients. Increases in MCT intake (particularly C8 and C10) and improvements in seizure outcomes (reduced seizure burden and intensity) and KD adherence also occurred with the 2.5:1 ratio feed in patients with the worst seizures and adherence, respectively.

Publisher

Wiley

Reference39 articles.

1. Ketogenic diet: overview, types, and possible anti-seizure mechanisms

2. National Institue for Health and Care Excellence (NICE).Epilepsies in children young people and adults.https://www.nice.org.uk/guidance/ng217. Accessed 23 Feb 2023

3. Worldwide Use of the Ketogenic Diet

4. Medium-chain triglycerides as a therapy for intractable childhood epilepsy

5. Medium‐chain triglyceride ketogenic diet, an effective treatment for drug‐resistant epilepsy and a comparison with other ketogenic diets;Liu Y‐M;Biom J,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3